Last reviewed · How we verify
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
This program is intended to provide access to sugemalimab for participants with R/R ENKTL, after their disease failed to respond to prior treatment regimen(s), preceding marketing authorization by the local regulatory agency.
Details
| Lead sponsor | EQRx International, Inc. |
|---|---|
| Status | NO_LONGER_AVAILABLE |
Conditions
- Extranodal NK/T-cell Lymphoma
Interventions
- sugemalimab
Countries
United States